March 25, 2021 | STAT
With time running out, an ALS patient fights with Biogen over expanded access to its drug
From STAT (subscription required to read the full article)
When Biogen declined to allow an ALS patient to participate in a clinical trial under compassionate use, questions arose about whether patients should be allowed to try potentially life-saving drugs without jeopardizing trial results.
“I do worry about a situation where somebody with privilege — they have some type of expertise, their finances or a professional network — or whatever it might be that allows them to gain access when people without those advantages can’t gain access,” said Steven Joffe, MD, PhD, interim chair of Medical Ethics & Health Policy.